Patents Examined by D Margaret M Seaman
  • Patent number: 10450274
    Abstract: Quinoline compounds and salts, hydrates or solvates serving as a selective uric acid reabsorption inhibitor, can be used in the treatment of hyperuricemia and gout by promoting uric acid to excrete from the body and reducing serum uric acid. Such compounds have the effect of reducing the uric acid in the animal body and human body.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: October 22, 2019
    Assignee: HINOVA PHARMACEUTICALS INC.
    Inventors: Lei Fan, Wu Du, Xinghai Li, Yuanwei Chen, Kexin Xu, Ke Chen, Shaohua Zhang, Tongchuan Luo
  • Patent number: 10442768
    Abstract: The present invention provides a method for producing a 2-aminonicotinic acid benzyl ester derivative. The method includes, as a step, reacting a 2-aminonicotinic acid derivative represented by the formula [I], wherein R1 represents a hydrogen atom or a C1 to C4 alkyl group and M represents an alkali metal, with a benzyl derivative represented by the formula [II], wherein R2 represents, for example, a hydrogen atom or a halogen atom, A represents, for example, a nitrogen atom, X represents a halogen atom, and Y represents, for example, an oxygen atom, in an aromatic hydrocarbon solvent in the presence of a phase transfer catalyst or a tertiary amine.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: October 15, 2019
    Assignee: AGRO-KANESHO CO., LTD.
    Inventors: Ryo Aizawa, Koichi Araki
  • Patent number: 10441570
    Abstract: This invention provides novel indole, indazole, benzimidazole, benzotriazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating hyperproliferations of the prostate including pre-malignancies and benign prostatic hyperplasia, prostate cancer, advanced prostate cancer, castration resistant prostate cancer, other AR-expressing cancers, androgenic alopecia or other hyper androgenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels (through degradation) and/or activity (through inhibition) of any androgen receptor including androgen receptor-full length (AR-FL) including pathogenic and/or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: October 15, 2019
    Assignees: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, GTX, INC.
    Inventors: Ramesh Narayanan, Duane D. Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He, Jayaprakash Pagadala, Charles B. Duke, Christopher C. Coss, James T. Dalton
  • Patent number: 10435370
    Abstract: The present invention relates to a compound of formula (I) wherein: Formula (II) means an aromatic ring wherein V is C or N and when V is N; Q is N or O, provided that R? does not exist when Q is O; R? independently represent a hydrogen atom or a group chosen among a (C1-C3)alkyl group, a halogen atom, a hydroxy! group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (Ci-C3)fluoroalkyl group, a —O—P(?O)—(OR3XOR4) group, a (C1-C4)alkoxy group and a —CN group, and can further be a group chosen among: (IIa), (IIIa) or anyone of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of an inflammatory disease.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: October 8, 2019
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal Tazi, Romain Najman, Florence Mahuteau, Didier Scherrer, Karim Chebli, Michael Hahne
  • Patent number: 10435371
    Abstract: Aminoquinoline compounds useful for treating chronic pain, addiction, and other conditions are provided. The aminoquinoline compound is represented by Formula (I): in which the substituents thereof are defined as set forth in the specification.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: October 8, 2019
    Assignee: LOHOCLA RESEARCH CORPORATION
    Inventor: Boris Tabakoff
  • Patent number: 10421739
    Abstract: The present invention relates to a process for the preparation of racemic nicotine from 3-pyridylaldehyde using a one-pot or step-wise method. The process comprises the following steps: Stetter reaction, reduction-cyclization and methylation.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: September 24, 2019
    Assignee: Council of Scientific & Industrial Research
    Inventors: Prathama Satyendra Mainkar, Kondepudi Sugnana Sunder, Togapur Pavan Kumar, Srivari Chandrasekhar
  • Patent number: 10421753
    Abstract: The present invention includes novel RAD51 inhibitors. The compounds of the invention may be useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: September 24, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jiewen Zhu, Wen-Hwa Lee, Hongyuan Chen, Xuning Guo, Xiao-Long Qiu
  • Patent number: 10413545
    Abstract: The present invention is directed to imidazolin-5-one derivatives, pharmaceutical compositions containing them, and their use as FASN inhibitors, in for example, the treatment of cancer, obesity related disorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein R1, R2, R3, R4, R5, m, n, and are defined herein.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: September 17, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Peter J Connolly, Tianbao Lu
  • Patent number: 10414765
    Abstract: The present application relates to novel (2-phenylimidazo[1,2-a]pyridin-3-yl)methyl-substituted perhydropyrrolo[3,4-c]pyrrole derivatives, to methods for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apneas and central sleep apneas and snoring.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: September 17, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Martina Delbeck, Michael Hahn, Thomas Müller, Heinrich Meier, Klemens Lustig, Johanna Mosig, Luisella Toschi, Udo Albus, Doris Gehring, Björn Rosenstein
  • Patent number: 10414752
    Abstract: The application relates to an inhibitor of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula (I-13):
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: September 17, 2019
    Assignee: Forma Therapeutics, Inc.
    Inventors: Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
  • Patent number: 10407393
    Abstract: Provided is a compound represented by formula (IV) or a salt thereof, wherein the content of the compound represented by formula (I) is 350 ppm by mass or less.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: September 10, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Taiju Nakamura, Taichi Abe, Yusuke Miyashita, Hirofumi Kuroda, Yusuke Ayata, Atsushi Akao
  • Patent number: 10407401
    Abstract: Disclosed is a novel, simple, scalable and environment friendly process for the synthesis of Oroxylin A from Baicalin. Baicalin is esterified to obtain a methyl ester which is further selectively methylated to provide Oroxylin A glucuronide methyl ester which on de-glycosylation results in the formation of Oroxylin A.
    Type: Grant
    Filed: August 4, 2018
    Date of Patent: September 10, 2019
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Rajendran Ramanujam, Hosahalli Prabhakara Hemantha
  • Patent number: 10391088
    Abstract: Analgesic compositions comprise an aminoquinoline together with an opioid, a non-steroidal anti-inflammatory drug (NSAID), a NE/5-HT reuptake inhibitor, or a combination thereof. The aminoquinoline potentiates bioactivity of opioids, NSAIDs and NE/5-HT reuptake inhibitors.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: August 27, 2019
    Assignee: Lohocla Research Corporation
    Inventor: Boris Tabakoff
  • Patent number: 10384090
    Abstract: A method of using select Schiff base compounds for chemical agent detoxification. The method including applying a compound to the contaminated substrate. The compound includes an imine having at least one Schiff base nitrogen and an alkyl substituent or an aryl substituent having an electron acceptor. The at least one Schiff base nitrogen is spaced away from the electron acceptor by a distance ranging from about 200 pm to about 1000 pm. The substrate and the compound are dried. The at least one Schiff base nitrogen of the compound promotes a nucleophilic attack on an electrophilic site of the toxic chemical agent.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: August 20, 2019
    Assignee: United States of America as represented by the Secretary of the Air Force
    Inventors: Jeffery Ray Owens, Wallace Bruce Salter, Katherine Moss Simpson
  • Patent number: 10377769
    Abstract: The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein X, Y, Z, R1, R2, R4 and R7 are defined herein.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: August 13, 2019
    Assignee: Forma Therapeutics, Inc.
    Inventors: Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E. R. Schiller, Adam C. Talbot, Mark J. Tebbe
  • Patent number: 10377739
    Abstract: A compound having the following formula: or a pharmaceutically acceptable salt thereof. A medicament or pharmaceutical composition contains the compound. A method of treating a respiratory tract disease includes administering to a patient an effective amount of a compound or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: August 13, 2019
    Assignee: OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES”
    Inventors: Vladimir Evgenievich Nebolsin, Tatyana Alexandrovna Kromova
  • Patent number: 10377743
    Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, R?, Q, W, X, Y, Z, n1, n2 and are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: August 13, 2019
    Assignee: Araxes Pharma LLC
    Inventors: Liansheng Li, Jun Feng, Yuan Liu, Pingda Ren, Yi Liu, Tao Wu, Yi Wang
  • Patent number: 10377717
    Abstract: Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: August 13, 2019
    Assignee: METACRINE, INC.
    Inventors: Nicholas D. Smith, Steven P. Govek
  • Patent number: 10358424
    Abstract: Provided are a sodium salt of a uric acid transporter inhibitor and a crystalline form thereof, In particular, provided are a uric acid transporter (URAT1) inhibitor 1-((6-bromo-quinoline-4-yl)thio)cyclobutyl sodium formate (the compound of formula (I)), a crystal form I, and preparation method thereof. The obtained crystal form I of the compound of formula (I) has a good crystal form stability and chemical stability, and the crystallization solvent used has a low toxicity and low residue, and can be better used in clinical treatment.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: July 23, 2019
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Guaili Wu, Zhenjun Qiu, Yunpeng Su, Xi Lu
  • Patent number: 10351547
    Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: July 16, 2019
    Assignee: CRINETICS PHARMACEUTICALS, INC.
    Inventors: Jian Zhao, Sangdon Han, Sun Hee Kim, Shimiao Wang, Yunfei Zhu